This article was originally published in The Tan Sheet
University of Pennsylvania researchers believe the findings of their new study suggest "the possibility of a new class of nonsteroidal anti-inflammatory drugs (NSAIDs) that steer clear of heart-disease risk and work to reduce it," according to a UPenn release. Deleting the inflammation enzyme microsomal (m)-PGE synthase (PGES)-1 gene in mice predisposed to hardening of the arteries had a "dramatic effect" on the development of atherosclerosis in male and female mice, Miao Wang, PhD, School of Medicine, UPenn, et al., found. Moreover, the deletion of mPGES-1 did not raise blood pressure or predispose the mice to thrombosis like COX-2 inhibition or deletion, the authors report in the Sept. 14 online edition of the Proceedings of the National Academy of Sciences. The PNAS study builds on a study published by the researchers earlier this year in the Journal of Clinical Investigation (1"The Tan Sheet" April 17, 2006, p. 8). The Journal of the American Medical Association released a study this week highlighting the cardiovascular risks associated with taking COX-2s...
You may also be interested in...
Researchers may have identified the mechanism by which COX-2 inhibitors contribute to the risk of cardiovascular events, a study published in the April Journal of Clinical Investigation finds
The Trump administration says a COVID-19 vaccine could be available in as little as 12 months, but most experts think that is overpromising unless safety or efficacy standards are sacrificed. Many are urging pivotal studies that look at clinical outcomes, not surrogates, for US FDA approval.
When asked about an inspector general report that found hospitals are struggling with tests and resources, and are looking to the federal government to help facilitate more efficient distribution of medical devices to fight the COVID-19 crisis, President Trump attacked the report as a political hit from an Obama holdover.